DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Tolmetin (Tolmetin Sodium) - Summary

 
 



Cardiovascular Risk

  • NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction (MI) and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk (see WARNINGS).
  • Tolmetin sodium is contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery (see CONTRAINDICATIONS and WARNINGS).

Gastrointestinal Risk

  • NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events (see WARNINGS)
 

TOLMETIN SUMMARY

Each tablet for oral administration contains 738 mg of tolmetin sodium, USP as the dihydrate in an amount equivalent to 600 mg of tolmetin. Each tablet contains 54 mg (2.

Carefully consider the potential benefits and risks of tolmetin sodium tablets and other treatment options before deciding to use tolmetin sodium tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS).

Tolmetin sodium tablets are indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis. Tolmetin is indicated in the treatment of acute flares and the long-term management of the chronic disease.

Tolmetin is also indicated for treatment of juvenile rheumatoid arthritis. The safety and effectiveness of tolmetin have not been established in pediatric patients under 2 years of age (see PRECAUTIONS: Pediatric Use and DOSAGE AND ADMINISTRATION).


See all Tolmetin indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Tolmetin

Positive results announced from follow-up study evaluating safety of a repeat injection of CINGAL for treatment of osteoarthritis of the knee
Source: Arthritis / Rheumatology News From Medical News Today [2015.07.10]
Anika Therapeutics, Inc., a leader in products for tissue protection, healing, and repair based on hyaluronic acid (HA) technology, have reported positive results from the CINGAL® 13-02 study...

Osteoarthritis Pictures Slideshow: Active Living From Day to Night
Source: MedicineNet Arthritis Specialty [2015.06.26]
Title: Osteoarthritis Pictures Slideshow: Active Living From Day to Night
Category: Slideshows
Created: 3/23/2012 12:00:00 AM
Last Editorial Review: 6/26/2015 12:00:00 AM

Osteoarthritis Pictures Slideshow: 10 Tips for Living Better Daily
Source: MedicineNet Arthritis Specialty [2015.06.23]
Title: Osteoarthritis Pictures Slideshow: 10 Tips for Living Better Daily
Category: Slideshows
Created: 2/15/2012 12:00:00 AM
Last Editorial Review: 6/23/2015 12:00:00 AM

Osteoarthritis Pictures Slideshow: Exercises for OA of the Knee
Source: MedicineNet Degenerative Disc Specialty [2015.06.17]
Title: Osteoarthritis Pictures Slideshow: Exercises for OA of the Knee
Category: Slideshows
Created: 2/18/2010 12:54:00 PM
Last Editorial Review: 6/17/2015 12:00:00 AM

Osteoarthritis Pictures Slideshow: Stay Active With Kids and Don't Let Arthritis Stop You
Source: MedicineNet meloxicam Specialty [2015.04.22]
Title: Osteoarthritis Pictures Slideshow: Stay Active With Kids and Don't Let Arthritis Stop You
Category: Slideshows
Created: 3/22/2012 12:00:00 AM
Last Editorial Review: 4/22/2015 12:00:00 AM

more news >>

Published Studies Related to Tolmetin

Morphological features of rat gastric mucosa after acute and chronic treatment with amtolmetin guacyl: comparison with non-selective and COX-2-selective NSAIDs. [2003]
BACKGROUND/AIMS: The compound amtolmetin guacyl (AMG) has been characterized in both animal and human studies as a novel non-selective non-steroidal anti-inflammatory drug (NSAID) endowed with lower ulcerogenicity in comparison with traditional NSAIDs due to a unique mechanism of action, namely the increase in endogenous production of gastric nitric oxide... CONCLUSION: Endothelial cell damage in the gastric microvasculature is an early event following both non-selective and COX-2-selective inhibitors. The low gastric mucosal toxicity of AMG is confirmed after acute and chronic treatment. Copyright 2003 S. Karger AG, Basel

[An evaluation of the therapeutic activity and tolerance of ST-679 in patients with osteoarthritis at different sites. A controlled double-blind study vs tolmetin] [1993.01]
A multicentered study was carried out, under double-blind conditions, on 160 elderly patients afflicted with differently localized symptomatic osteoarthritis, for the purpose of evaluating the therapeutical efficacy and tolerability of ST-679 (per-os at a dose of 1200 mg pro die in 80 patients) and to compare them with those of tolmetin (per os at a dose of 1200 mg pro die in 80 patients).

Double-blind, placebo-controlled endoscopic comparison of the mucosal protective effects of misoprostol versus cimetidine on tolmetin-induced mucosal injury to the stomach and duodenum. [1988.08]
Ninety normal volunteers were entered into a double-blind, placebo-controlled study to compare the efficacy of misoprostol (200 micrograms q.i.d.) vs... It is concluded that misoprostol is highly effective and significantly better than cimetidine in protecting the gastric mucosa from tolmetin-induced injury; however, both agents were highly protective in the duodenum.

A crossover study of naproxen, diclofenac and tolmetin in seronegative juvenile chronic arthritis. [1988.04]
Nonsteroidal anti-inflammatory drugs (NSAID) are useful in the management of juvenile chronic arthritis (JCA) and efficacy has usually been compared with aspirin... America, therefore naproxen or diclofenac are recommended as the first line of treatment in children with chronic arthritis over the age of 5.

more studies >>


Page last updated: 2015-07-10

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015